bryan johnson

Psychedelics act as longevity interventions by annihilating the default mode network, triggering neuroplasticity, reducing inflammation, and producing measurable metabolic resets (blood glucose improvement from 99.5th to 99.9th percentile) and microbiome shifts — positioning them as unique 'psychological rejuvenation' tools distinct from diet, exercise, or sleep.

FoxO3 gene delivery via mesenchymal stem cells achieved over 50% tissue rejuvenation across multiple organs in preclinical studies — described as 'the best demonstration in the entire world for tissue regeneration' — with Johnson actively contacting the Chinese research team for replication and potential self-administration.

Autologous mitochondrial transplantation using young donor mitochondria (maternally matched) coated in red blood cell envelopes for immune evasion represents a 'whole therapeutic modality no one has recognized' — Johnson is proceeding with Phase 2 trial via third-party bioreactor, targeting mitochondrial DNA degradation as a core aging driver.

Johnson has generated iPSC-derived organoids (heart, liver, lung) from his own cells to test molecules in vitro before self-administration — creating a personalized 'digital twin' platform for combinatorial therapy optimization, dose-finding, and safety screening that compresses experimental timelines.

NewLimit's AI-driven computational approach has dramatically accelerated discovery of safe Yamanaka factor combinations and dosing regimens, solving the critical oncogenic risk of overdosing — Johnson theorizes the ultimate solution requires 'cellular switches' with real-time gene expression feedback loops for precise in vivo control.

Johnson notes AI capabilities for managing complex biotech programs (gene therapy construction, trial design) have transformed 'so different now, 6 months later' — suggesting AI-accelerated R&D execution is becoming a critical competitive advantage in longevity biotech.